InvestorsHub Logo
Followers 0
Posts 4035
Boards Moderated 0
Alias Born 10/31/2017

Re: BullsOnFire post# 13287

Thursday, 05/17/2018 9:16:27 AM

Thursday, May 17, 2018 9:16:27 AM

Post# of 18666
OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to BiKEs. (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-50% for BiKE)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTBP News